149 related articles for article (PubMed ID: 37462782)
21. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
Kang L; Guo Y; Zhang X; Meng J; Wang ZY
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
[TBL] [Abstract][Full Text] [Related]
22. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
Adewumi AT; Mosebi S
Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
[TBL] [Abstract][Full Text] [Related]
23. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
[TBL] [Abstract][Full Text] [Related]
24. Expression Significance of Estrogen Receptor ER-α36 in Breast Cancer Treated by Chemotherapy: A Meta-Analysis.
He E; Xia X; Quan H; Leng P
Mol Biotechnol; 2024 May; 66(5):991-999. PubMed ID: 38270756
[TBL] [Abstract][Full Text] [Related]
25. Predictive and prognostic value of ER-α36 expression in breast cancer patients treated with chemotherapy.
Yu L; Ke W; Wang Y; Ding W; Wang B; Huang S; Chen J; Wang X; Wang Z; Shen P
Steroids; 2014 Jun; 84():11-6. PubMed ID: 24632025
[TBL] [Abstract][Full Text] [Related]
26. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
[TBL] [Abstract][Full Text] [Related]
28. Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells.
Yin L; Qi XW; Liu XZ; Yang ZY; Cai RL; Cui HJ; Chen L; Yu SC
Oncol Lett; 2020 Jun; 19(6):3950-3958. PubMed ID: 32382339
[TBL] [Abstract][Full Text] [Related]
29. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
30. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors.
Gu Y; Chen T; López E; Wu W; Wang X; Cao J; Teng L
J Transl Med; 2014 Jan; 12():16. PubMed ID: 24447535
[TBL] [Abstract][Full Text] [Related]
31. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66.
Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
Biochem Biophys Res Commun; 2005 Nov; 336(4):1023-7. PubMed ID: 16165085
[TBL] [Abstract][Full Text] [Related]
32. Role of ER-α36 in breast cancer by typical xenoestrogens.
Liu J; Xu Z; Ma X; Huang B; Pan X
Tumour Biol; 2015 Sep; 36(10):7355-64. PubMed ID: 26337277
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
34. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.
Sun Q; Liang Y; Zhang T; Wang K; Yang X
Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071
[TBL] [Abstract][Full Text] [Related]
35. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
Zhang X; Ding L; Kang L; Wang ZY
PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
[TBL] [Abstract][Full Text] [Related]
38. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
39. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
40. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
